Conducted across four sites in Manchester, ORI-01 enrolled 106 patients, with 66 diagnosed with inflammatory bowel disease (IBD). The study compared rectal mucus calprotectin levels with faecal calprotectin in patients both with and without IBD. The results demonstrated a strong positive correlation between mucus and faecal calprotectin, validating the principle of using rectal mucus for non-invasive inflammation monitoring. The study led to the development of a successful collection kit and was later published in July 2021. These findings provided a robust foundation for future work in point-of-care IBD disease activity monitoring.